Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The pilot plant is focused on scaling up beverage production and will support applications
To accelerate the development of next-generation radioconjugates to treat cancer
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Women emerge as the cornerstone of this monumental undertaking
The inspection was concluded with few procedural observations
Subscribe To Our Newsletter & Stay Updated
